Plain-English translation of NCT01909453 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compared three different treatment approaches for people with advanced melanoma (a serious type of skin cancer) that had a specific genetic mutation called BRAF V600. Participants were randomly assigned to receive either combined with , alone, or . The study examined how well each medication or combination worked and what side effects patients experienced.
Advanced melanoma is a serious condition that can spread throughout the body, and doctors wanted to find the most effective and safest treatment option for patients whose cancer had this particular genetic mutation. This medication combination and dosages had shown promise in earlier testing, and the trial aimed to prove which approach worked best.
Participants received one of the assigned medication regimens, taken by mouth either once or twice daily depending on their assigned group. The trial took place at multiple medical centers, and participants attended regular visits for monitoring—including blood tests, imaging scans, and physical exams—to track how well the medication was working and to watch for any side effects. The study was split into two parts to help researchers refine the best dose and combination based on early results.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States